Novel approaches to tuberculosis prevention: DNA vaccines

Scandinavian Journal of Infectious Diseases

Volumn 46, Issue 3, 2014, Pages 161-168

  Rivas Santiago, Bruno ^a   Cervantes Villagrana, Alberto R ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE ZACATECAS   (Mexico)

Author keywords

Adjuvant; DNA vaccine; Tuberculosis

Indexed keywords

ANIMALS; ANTIGENS, BACTERIAL; HUMANS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA;

EID: 84894354119     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.871645     Document Type: Review

References (56)

1. Glaziou P, Falzon D, Floyd K, Raviglione M. Global epidemiology of tuberculosis. Semin Respir Crit Care Med 2013;34:3-16.
2. Moss AR, Alland D, Telzak E, Hewlett D Jr, Sharp V, Chiliade P, et al. A city-wide outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in New York. Int J Tuberc Lung Dis 1997;1:115-21.
3. Jarand J, Shean K, O'Donnell M, Loveday M, Kvasnovsky C, Van der Walt M, et al. Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. Trop Med Int Health 2010;15:1179-84.
4. Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, et al. Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. PLoS One 2012;7:e31786.
5. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009;136:420-5.
6. Brewer TF. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000;31(Suppl 3):S64-7.
7. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45.
8. Rook GA, Dheda K, Zumla A. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting? Vaccine 2005;23:2115-20.
9. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 2012;8:e1002607.
10. Romano M, Aryan E, Korf H, Bruffaerts N, Franken CL, Ottenhoff TH, et al. Potential of Mycobacterium tuberculosis resuscitation-promoting factors as antigens in novel tuberculosis sub-unit vaccines . Microbes Infect 2012;14:86-95.
11. Acosta A, Norazmi MN, Hernandez-Pando R, Alvarez N, Borrero R, Infante JF, et al. The importance of animal models in tuberculosis vaccine development. The Malaysian Journal of Medical Sciences 2011;18:5-12.
12. Sambandamurthy VK, Jacobs WR Jr. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 2005;7:955-61.
13. Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis 2005;85:29-38.
14. Kondratieva T, Rubakova E, Kana BD, Biketov S, Potapov V, Kaprelyants A, Apt A. Mycobacterium tuberculosis attenuated by multiple deletions of rpf genes effectively protects mice against TB infection . Tuberculosis 2011;91:219-23.
15. Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, Penn E, et al. Novel recombinant BCG expressing perfrin-golysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009;27:4412-23.
16. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 2008;198:1491-501.
17. Pal PG, Horwitz MA. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun 1992;60:4781-92.
18. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6 . Infect Immun 2001;69:2773-8.
19. Denis O, Tanghe A, Palfliet K, Jurion F, van den Berg TP, Vanonckelen A, et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4 + and CD8 +T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun 1998;66:1527-33.
20. Cervantes-Villagrana AR, Hernandez-Pando R, Biragyn A, Castaneda-Delgado J, Bodogai M, Martinez-Fierro M, et al. Prime-boost BCG vaccination with DNA vaccines based in beta-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model. Vaccine 2013;31:676-84.
21. KitaY, Tanaka T,Yoshida S, Ohara N, KanedaY, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005;23:2132-5.
22. Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation . Vaccine 2006;24:1191-204.
23. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Evaluation of a novel vaccine (HVJ-liposome/ HSP65 DNA+ IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB . Vaccine 2007;25:2990-3.
24. Biragyn A. Defensins - non-antibiotic use for vaccine development. Curr Protein Pept Sci 2005;6:53-60.
25. Garg S, Oran A, Wajchman J, Sasaki S, Maris CH, Kapp JA, Jacob J. Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol 2003;4:907-12.
26. Coban C, Koyama S, Takeshita F, Akira S, Ishii KJ. Molecular and cellular mechanisms of DNA vaccines. Hum Vaccin 2008;4:453-6.
27. Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. J Clin Invest 2004;114:1241-4.
28. Babiuk S, Mookherjee N, Pontarollo R, Griebel P, van Drunen Littel-van den Hurk S, Hecker R, Babiuk L. TLR9 - / - and TLR9+/+ mice display similar immune responses to a DNA vaccine . Immunology 2004; 113:114-20.
29. Huygen K, Content J, Denis O, Montgomery DL,Yawman AM, Deck RR, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine . Nature Med 1996;2:893-8.
30. Goncalves ED, Bonato VL, da Fonseca DM, Soares EG, Brandao IT, Soares AP, et al. Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming. Genet Vaccines Ther 2007;5:7.
31. Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999;67:1702-7.
32. Ulmer JB, Liu MA, Montgomery DL,Yawman AM, Deck RR, DeWitt CM, et al. Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination. Vaccine 1997;15:792-4.
33. Tanghe A, D'Souza S, Rosseels V, Denis O, Ottenhoff TH, Dalemans W, et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 2001;69:3041-7.
34. Wang QM, Sun SH, Hu ZL, Yin M, Xiao CJ, Zhang J C. Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting. Vaccine 2004;22:3622-7.
35. Skeiky YA, Ovendale PJ, Jen S, Alderson MR, Dillon DC, Smith S, et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol 2000; 165:7140-9.
36. Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E, et al. Therapy of tuberculosis in mice by DNA vaccination . Nature 1999;400:269-71.
37. Roche PW, Peake PW, Billman-Jacobe H, Doran T, Britton WJ. T-cell determinants and antibody binding sites on the major mycobacterial secretory protein MPB59 of Mycobacterium bovis . Infect Immun 1994;62:5319-26.
38. Zhang X, Divangahi M, Ngai P, Santosuosso M, Millar Zganiacz A, et al. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene . Vaccine 2007;25:1342-52.
39. Dou J, Wang Y, Yu F, Yang H, Wang J, He X, et al. Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting. Int J Immunogenet 2012;39:183-90.
40. Hu D, Wu ., Zhang R, Chen L. T-bet acts as a powerful adjuvant in Ag85B DNA-based vaccination against tuberculosis. Mol Med Rep 2012;6:139-44.
41. Wozniak TM, Ryan AA, Triccas JA, Britton WJ. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection . Infect Immun 2006;74:557-65.
42. Satkauskas S, Bureau MF, Mahfoudi A, Mir LM. Slow accumulation of plasmid in muscle cells: supporting evidence for a mechanism of DNA uptake by receptor-mediated endo-cytosis. Mol Ther 2001;4:317-23.
43. Jeon BY, Eoh H, Ha SJ, Bang H, Kim SC, Sung YC, Cho SN. Co-immunization of plasmid DNA encoding IL-12 and IL-18 with bacillus Calmette-Guerin vaccine against progressive tuberculosis. Yonsei Med J 2011;52:1008-15.
44. Wang J, Snider DP, Hewlett BR, Lukacs NW, Gauldie J, Liang H, et al. Transgenic expression of granulocyte-macrophage colony-stimulating factor induces the differentiation and activation of a novel dendritic cell population in the lung. Blood 2000;95:2337-45.
45. Fyall KM, Fong AM, Rao SB, Ibrahim JG, Waxweiler WT, Thomas NE. The TBX21 transcription factor T-1993C polymorphism is associated with decreased IFN-gamma and IL-4 production by primary human lymphocytes. Hum Immunol 2012;73:673-6.
46. Chaparas SD. Immunity in tuberculosis. Bull World Health Organ 1982;60:447-62.
47. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002;298:1025-9.
48. Biragyn A, Coscia M, Nagashima K, Sanford M, Young HA, Olkhanud P. Murine beta-defensin 2 promotes TLR-4/ MyD88-mediated and NF-kappaB-dependent atypical death of APCs via activation of TNFR2. J Leukoc Biol 2008;83: 998-1008.
49. Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, Klyushnenkova E, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmu-nogenic tumor antigens. J Immunol 2001;167:6644-53.
50. Marquina-Castillo B, Garcia-Garcia L, Ponce-de-Leon A, Jimenez-Corona ME, Bobadilla-Del Valle M, Cano-Arellano B, et al. Virulence, immunopathology and transmissibility of selected strains of Mycobacterium tuberculosis in a murine model. Immunology 2009;128:123-33.
51. Hernandez-Pando R, Marquina-Castillo B, Barrios-Payan J, Mata-Espinosa D. Use of mouse models to study the variability in virulence associated with specific genotypic lineages of Mycobacterium tuberculosis. Infect Genet Evol 2012;12: 725-31.
52. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses . Sci Transl Med 2012;4:155ra38.
53. Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother 2012;61:2161-70.
54. Vardas E, Stanescu I, Leinonen M, Ellefsen K, Pantaleo G, Valtavaara M, et al. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(R)-Multi-HIVB, in untreated HIV-1 infected subjects . Vaccine 2012;30:4046-54.
55. SaekiY, Matsumoto N, NakanoY, Mori M, Awai K, KanedaY. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997;8:2133-41.
56. World Health Organization. Guidelines for assuring the quality and nonclinical safety evaluation of DNA vaccines. World Health Organ Tech Rep Ser 2007; Annex 1